Another novel nano-liposomal formulation, containing PLB and the genistein drug, synergistically inhibits xenograft prostate tumour growth by ∼80% without any significant toxicity, as well as decreasing the number of Glut-1 transporters for retarding tumour growth [203]. This evidence concerns the gene SLC2A1 and neoplasm.